QUICKLINKS AND VIEW OPITONS
Two year weight loss with Xenical vs Alli vs placebo: 12.3 lbs vs 9.9 lbs vs 6.9 lbs
Monday, July 16, 2007 8:23 am Email this article
After patients had lost an average of 19.3 pounds with Xenical (orlistat) plus a reduced-calorie diet, half of them continued taking Xenical (120 mg of orlistat) three times per day plus a weight maintenance diet for another year, while the other half of patients were given Alli (60 mg of orlistat) instead. Weight loss at the end of the second year was 12.3 pounds for those who kept taking Xenical (120 mg of orlistat) versus 9.9 pounds for those given Alli (60 mg of orlistat) compared to 6.9 pounds for those who were switched from Xenical to a placebo. Weight Regain
Weight regain after second year: 7 lbs vs 9.4 lbs vs 12.4 lbs
The amount of weight that was regained by the end of the second year was 7 pounds for those who remained on Xenical (120 mg of orlistat), which was a weight regain of roughly one-third of the weight they had lost; 9.4 pounds regained for those who were switched from Xenical (120 mg of orlistat) to Alli (60 mg of orlistat), which was roughly one-half the weight they had lost; and 12.4 pounds for those who switched from Xenical (120 mg of orlistat) to a placebo, which was roughly two-thirds of the weight they had lost.
Percent Weight Loss after Two Years
Percent Weight Loss after Two Years: 7.6% with Xenical vs 4.5% with placebo vs 4.2% with placebo one year and Xenical the second year
At the end of two years, the average weight loss for those taking Xenical (120 mg of orlistat) the entire time was 7.6 percent of body weight compared to 4.5 percent for the those taking a placebo and 4.2 percent for those who were switched from placebo to Xenical (120 mg of orlistat) in the second year.
10% Weight Loss
10% weight loss: 34% vs 18%
After two years, twice as many patients taking 120 mg of Xenical (120 mg of orlistat) maintained a 10 percent weight loss as those taking the placebo—34 percent versus 18 percent.
Davidson M, Hauptman J, Digirolamo M, Foreyt J, Halsted C, Heber D, Heimburger D, Lucas CP, Robbins D, Chung J, Heymsfield S. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial. JAMA. 1999 Jan 20, 281(3):235-42.
AUTHOR’S CONTACT INFORMATION
Michael H. Davidson, M.D.
Chicago Center for Clinical Research,
Chicago, Illinois, USA
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2017 - Larry Hobbs - All Rights Reserved.